Latest news with #UCB-SC
Yahoo
16-05-2025
- Business
- Yahoo
Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products. As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery—key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach. OTCQB Up ListingTo view an enhanced version of this graphic, please visit: Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work—such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)—while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities. "We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence." With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
14-04-2025
- Business
- Yahoo
Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Winter Park, Florida--(Newsfile Corp. - April 14, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products. As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery-key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach. Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work-such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)-while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities. "We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence." With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
07-04-2025
- Business
- Yahoo
Adia Nutrition Inc. Completes Independent Audit with Astra Audit and Advisory LLC., Prepares to File for OTCQB Uplisting
Winter Park, Florida--(Newsfile Corp. - April 7, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a pioneering force in advanced stem cell therapies and nutritional wellness, is proud to announce the successful completion of its independent audit, a crucial milestone that positions the company to file for uplisting to the OTCQB market. This achievement marks a significant step in Adia Nutrition's journey to enhance transparency, build investor confidence, and amplify shareholder value as it continues to revolutionize healthcare through its innovative treatment offerings and wellness solutions. The audit, conducted with precision by Astra Audit and Advisory LLC., a PCAOB-registered auditing firm, was completed efficiently and thoroughly. This process reviewed the company's financials and operations, ensuring compliance with the heightened standards required for the OTCQB tier-a market that demands rigorous reporting and offers greater visibility compared to the OTC Pink market. The successful audit is a testament to Adia Nutrition's commitment to financial integrity as it scales its primary business of providing cutting-edge stem cell therapies, including Umbilical Cord Stem Cell (UCB-SC) treatments and Autologous Hematopoietic Stem Cell Transplantation (aHSCT), to patients nationwide. "We are incredibly excited to reach this point," said Larry Powalisz, CEO of Adia Nutrition Inc. "Completing this audit is a vital step in our uplisting to the OTCQB, reflecting our team's dedication to excellence. This milestone not only strengthens our credibility but also supports our mission to deliver life-changing stem cell therapies to patients while creating value for our shareholders. As we accelerate our growth, we remain committed to advancing regenerative medicine and nutritional wellness with science-backed solutions." The move to OTCQB highlights Adia Nutrition's focus on operational excellence and shareholder trust as it expands its network of clinics delivering advanced stem cell treatments and complementary nutritional products. With the audit finalized, the company is poised to swiftly advance its filing process with the OTC Markets Group, enhancing its market presence and investor appeal. This uplisting will provide greater liquidity and exposure, supporting Adia Nutrition's ambitious goals of treating patients with innovative therapies, such as UCB-SC for inflammation and aHSCT for autoimmune conditions like Multiple Sclerosis, while driving sustainable growth and long-term value for its stakeholders. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
Associated Press
02-04-2025
- Business
- Associated Press
Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine
Stem cells have a unique ability—they can transform into different types of cells, making them a game-changer in regenerative medicine. From repairing heart tissue after a heart attack to potentially reversing neurodegenerative diseases like Alzheimer's, the possibilities are vast. While their potential has been known for years, challenges such as immune rejection and difficulty in controlling cell differentiation have slowed progress. However, advances in DNA and RNA research have given scientists better control over the process, opening the door to real-world treatments. The stem cell industry is now shifting from theoretical breakthroughs to tangible medical applications. In 2024, the global stem cell market was valued at $15.1 billion and is projected to grow at an annual rate of 11.41% through 2030. This surge is driven by increased research, growing demand for stem cell banking, and major strides in precision medicine. Now, let's take a closer look at a few stocks making waves in this sector. ADIA Nutrition Inc. (OTC Pink: ADIA) is quickly becoming a company to watch in the stem cell and regenerative medicine space. The company operates through two main divisions: a nutritional supplement business and its medical division, Adia Med, which is focused on advanced stem cell therapies. ADIA's recent announcements and strong growth trajectory suggest the company is positioning itself as a leader in this high-potential sector. One of the company's standout moves is its commitment to expanding stem cell treatments across the United States. In January 2025, ADIA opened its flagship clinic in Winter Park, Florida, where it already offers treatments using umbilical cord stem cells (UCB-SC) to address conditions like Multiple Sclerosis, orthopedic injuries, and joint pain. The clinic exceeded financial expectations in its first month, covering all startup costs and proving that there is strong demand for its therapies. This success set the stage for further growth, including the opening of satellite locations across the country. ADIA's medical division, Adia Med, is also making waves with its decision to offer Therapeutic Plasma Exchange (TPE) at all future full-service clinic locations. TPE, which removes harmful substances from a patient's blood, is being used to treat a variety of conditions, including Alzheimer's disease. This is a major move in a rapidly growing field. According to ADIA's CEO, Larry Powalisz, 'Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care.' This technology sets ADIA apart from other players in the field and positions the company to lead in advanced treatment options for patients with neurodegenerative diseases. Another area where ADIA is taking a leadership role is in the standardization of stem cell treatments. The company is working on setting new quality and safety standards for umbilical cord stem cell use in the United States. With many clinics offering subpar or non-viable stem cells, ADIA is aiming to make sure every patient gets stem cells that are live and effective. As CEO Larry Powalisz stated, 'We're crafting a movement for reliability and excellence.' The company plans to present its standards to the FDA and the Department of Health and Human Services, pushing for nationwide regulations that could transform the entire stem cell industry. On top of that, ADIA is preparing to expand internationally, as multiple overseas organizations have expressed interest in licensing the company's treatments. The company is already in the process of reviewing the legal and regulatory steps required to bring its innovative therapies, like its flagship Adia Vita stem cell product, to other markets. ADIA's international expansion could help it tap into a global market for regenerative medicine, offering the company even more room to grow. Lastly, ADIA's asset-light expansion model is another key factor driving its growth. In March 2025, the company opened its first satellite clinic in Tinton Falls, New Jersey, in partnership with Keep Glowing Medical Spa and Dr. Michael Ellis. This shared space partnership allows ADIA to expand quickly without the overhead costs of building new clinics from the ground up. The Tinton Falls location will offer ADIA's stem cell therapies, including Adia Vita and AdiaLink, to patients seeking advanced treatments for a variety of conditions. ADIA Nutrition's combination of strong financial performance, strategic partnerships, and commitment to innovative treatments makes it an exciting stock to watch in the stem cell space. With its focus on quality, expanding treatment options, and international growth, ADIA is positioning itself to be a leader in regenerative medicine. Investors looking for a company with significant growth potential in this booming sector should keep an eye on ADIA as it continues to expand and evolve. Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that is making strides in developing stem cell therapies for both cancer and autoimmune diseases. The company's approach is built around induced pluripotent stem cells (iPSCs), which can be used to create cell therapies that are ready to be used right off the shelf. This eliminates some of the challenges of traditional stem cell treatments, which require personalized, patient-specific cells. By creating universal, off-the-shelf therapies, Fate aims to make stem cell treatments more accessible and cost-effective. One of the most promising candidates in Fate's pipeline is FT819, a type of CAR T-cell therapy designed to treat autoimmune diseases, particularly systemic lupus erythematosus (SLE). FT819 is especially notable because it doesn't require the usual chemotherapy conditioning that other CAR T-cell therapies do. Early trials of FT819 have shown strong potential. The first three patients treated with FT819 experienced no dose-limiting toxicities, and one patient even went into remission after the treatment. Bob Valamehr, Fate's President of Research and Development, expressed his excitement over the results, saying, 'We are pleased with the early clinical data, which continues to support the potential for disease transformation.' In addition, the FDA has allowed Fate to expand its trials to include additional autoimmune diseases, which could broaden the market for FT819 significantly. Fate's pipeline doesn't stop with FT819. The company is also advancing other therapies, like FT825 and FT522, which target different types of cancers. FT825 is designed to treat solid tumors, while FT522 focuses on blood cancers. Like FT819, these therapies aim to simplify the treatment process by avoiding the need for chemotherapy conditioning. FT522, for example, uses natural killer (NK) cells to target B-cell cancers, offering a promising new way to treat patients with difficult-to-treat cancers. On the financial side, Fate Therapeutics is well-funded, with $307 million in cash and investments at the end of 2024. This gives the company plenty of resources to continue advancing its clinical programs, and the company's strong partnerships with firms like Ono Pharmaceutical further enhance its growth potential. With its innovative approach to off-the-shelf stem cell therapies, Fate Therapeutics is positioning itself as a leader in the field. Its therapies for autoimmune diseases and cancer are showing real promise, and with strong financial backing, the company is poised for continued progress in the years ahead. Mesoblast Limited (NASDAQ: MESO) is a global leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe, life-threatening inflammatory diseases. The company's therapies leverage its proprietary mesenchymal stromal cell (MSC) technology, which works by releasing anti-inflammatory factors to help modulate the immune system and reduce harmful inflammation. This technology is aimed at addressing conditions like steroid-refractory acute graft-versus-host disease (SR-aGvHD) and chronic heart failure, among others. Mesoblast's FDA-approved product, Ryoncil (remestemcel-L), is the first MSC-based therapy to gain approval for the treatment of pediatric patients with SR-aGvHD, a life-threatening condition that occurs after bone marrow transplants. In December 2024, the U.S. FDA approved Ryoncil for use in children as young as two months old, marking a significant milestone for the company. The therapy has demonstrated strong clinical results, with a 70% overall response rate in a Phase 3 trial and a survival rate of 49% at four years for children treated with Ryoncil. The company is also working on expanding Ryoncil's applications to other inflammatory diseases, such as adult SR-aGvHD and biologic-resistant inflammatory bowel disease (IBD). Furthermore, Mesoblast is advancing its second key product, Rexlemestrocel-L (Revascor), which is being studied for chronic heart failure and chronic low back pain. These treatments offer promising alternatives to existing therapies by addressing the underlying inflammation that often complicates these diseases. In terms of growth and financial stability, Mesoblast has been proactive in securing strategic partnerships and expanding its market presence. The company has agreements in key regions such as Japan, Europe, and China. Additionally, it has an extensive intellectual property portfolio, with over 1,000 granted patents covering MSC compositions, manufacturing methods, and therapeutic indications. Financially, Mesoblast is in a strong position, with a cash balance of $38 million at the end of 2024. The company raised an additional $161 million in a private placement, which bolsters its ability to continue advancing its research and development initiatives. Mesoblast's CEO, Dr. Silviu Itescu, expressed his enthusiasm about the future, noting, 'Our FDA-approved product Ryoncil will be available in the coming weeks to children with SR-aGvHD in need of life-saving therapy.' Overall, Mesoblast's strong pipeline of therapies and its leadership in the allogeneic cell medicine space position it as a promising company in the stem cell and regenerative medicine sectors. With its recent FDA approval and expanding commercial partnerships, Mesoblast is set to make a significant impact in treating inflammatory diseases globally. CRISPR Therapeutics (NASDAQ: CRSP) is a pioneer in gene editing, making history as the first company to bring a CRISPR-based therapy to market. The company's flagship product, CASGEVY, was approved in multiple countries in late 2023 to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)—two serious genetic blood disorders. Since then, patient demand has been strong, with over 50 authorized treatment centers (ATCs) worldwide and more than 50 patients having initiated cell collection by the end of 2024. Looking ahead, 2025 is shaping up to be a big year for CRISPR Therapeutics. The company is working on next-generation gene-editing programs and expanding into new disease areas like oncology, autoimmune disorders, and cardiovascular diseases. CEO Samarth Kulkarni called 2025 a 'milestone-rich year' with major clinical updates expected across the company's pipeline. While CASGEVY's commercial rollout continues, CRISPR Therapeutics is making progress on several other fronts. CTX112 is a next-generation CAR T-cell therapy for blood cancers and autoimmune diseases. Early results showed strong efficacy in lymphoma patients, earning it a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. In cardiovascular disease, CTX310 and CTX320 are experimental therapies targeting cholesterol and lipoprotein(a), a genetic risk factor for heart disease. Clinical updates are expected in the first half of 2025. CTX211 is a gene-edited stem cell therapy for Type 1 diabetes (T1D), designed to free patients from insulin injections without needing long-term immune suppression. CRISPR Therapeutics ended 2024 with $1.9 billion in cash and investments, giving it a strong financial cushion to fund research and commercialization efforts. The company has also partnered with Vertex Pharmaceuticals on CASGEVY, benefiting from Vertex's commercial expertise as they roll out the therapy globally. Disclaimers: RazorPitch Inc. 'RazorPitch' is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact City: NAPLES State: Florida Country: United States
Yahoo
01-04-2025
- Business
- Yahoo
Judge Orders Cancellation of Over 25 Million Adia Nutrition Shares, Bolstering Shareholder Value
Winter Park, Florida--(Newsfile Corp. - April 1, 2025) - Adia Nutrition (OTC Pink: ADIA), a leader in innovative nutritional solutions, is pleased to announce a significant milestone for its shareholders following a recent court ruling. A judge has ordered the cancellation of over 25 million shares of Adia Nutrition stock, including more than 15 million restricted common shares and 10 million preferred shares. This landmark decision will reduce the company's outstanding shares by over 15 million, with Adia Nutrition having already contacted the transfer agent to initiate the share cancellation process, marking a pivotal step in enhancing shareholder value. Adia Nutrition Share Structure Before CancellationTo view an enhanced version of this graphic, please visit: The cancellation of these shares—comprising over 15 million restricted shares and 10 million preferred shares—reflects Adia Nutrition's commitment to optimizing its capital structure. This reduction in outstanding shares is expected to increase the value of remaining shares by concentrating ownership and improving earnings per share metrics, directly benefiting current investors. "This ruling is a win for our shareholders," said Larry Powalisz, CEO of Adia Nutrition. "By reducing the total number of outstanding shares, we're strengthening the company's financial foundation and enhancing the value of each share held by our loyal investors. This is just the beginning of our efforts to deliver long-term growth and stability." Adia Nutrition anticipates further strategic initiatives in the near future, signaling that more positive developments are on the horizon. The company remains dedicated to transparency and maximizing shareholder returns as it continues to innovate in the nutrition and wellness sector. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
